查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1446442

北美分子诊断市场规模、份额、趋势分析报告：按产品、测试地点、技术、应用、国家和细分市场预测，2024-2030

North America Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Others), By Test Location, By Technology (PCR, ISH, INAAT, Sequencing), By Application, By Country, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

北美分子诊断市场成长与趋势：

Grand View Research, Inc.最新报告显示，2030年北美分子诊断市场规模预计将达到72.3亿美元，2024年至2030年复合年增长率为4.2%。

技术先进产品的推出预计将带动北美市场的发展。分子诊断技术的进步使得许多疾病得以早期发现，减少了严重的经济和社会负担的可能性。分子诊断技术利用PCR、定序和遗传技术来实现癌症、遗传疾病和感染疾病的早期诊断。

阿兹海默症、透纳氏症、帕金森氏症等慢性疾病以及感染疾病和遗传疾病的盛行率不断上升，预计将在预测期内提振市场需求。据美国疾病管制与预防中心 (CDC) 称，美国每年有十分之七的死亡病例是由癌症、糖尿病、慢性肾臟病和呼吸系统疾病等慢性病造成的。此外，甲型和乙型流感等疾病的增加预计也将推动市场成长。例如，根据美国疾病管制与预防中心 (CDC) 估计，2021-2022 年流感季节期间将有 900 万人感染流感。

用于分子诊断临床研究的外部资金的增加预计将推动市场的发展。资金筹措在产品开发过程中扮演重要角色。例如，2023 年 4 月，Promega 公司宣布在 2023 年津贴15,000 美元，用于使用 qPCR 的学术生命科学研究。同样，2023 年 6 月，Accelerate Diagnostics, Inc. 获得了 2,400 万美元，用于加速其 Wave 平台和新型快速测试的开发。透过这些倡议，预计中小企业将参与新分子诊断测试的开发。

北美分子诊断领域的主要企业继续努力透过推出新产品并以更先进、更有效率的产品满足买家不断变化的需求来获得竞争优势。例如，2022年11月，丹纳赫子公司Cepheid推出了多重阴道检测组合（MVP），这是一种PCR检测，可检测滴虫病、细菌性念珠菌症和外阴阴道念珠菌病等多种疾病。

此外，製造商和公司之间为开发新型疗法而加强的策略合作伙伴关係预计将推动市场成长。例如，2023年2月，Thermo Fisher Scientific Inc.与MyLab合作购买了针对结核病和HIV等多种感染疾病的RT-PCR套件。此外，2023 年 1 月，QIAGEN 和 Helix 达成独家合作，以增强遗传疾病的次世代定序仪伴同性伴随诊断。

北美分子诊断市场报告亮点：

  • 以产品来看，由于效率和成本效益的提高，试剂细分市场在2023年占据北美分子诊断领域最大的销售份额。
  • 由于市场渗透率高、测试量大，2023年北美分子诊断市场由中心实验室领域主导。
  • 从技术上来看，PCR领域将在2023年主导北美分子诊断市场，是医师和病患临床诊断最首选的技术。
  • 由于北美感染疾病高发生，感染疾病领域引领2023年应用领域。
  • 由于有利的报销政策、主要参与者在当地的存在以及成熟的医疗基础设施，美国在该区域市场占据主导地位。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影响分析

第四章北美分子诊断市场：产品业务分析

  • 北美分子诊断市场：产品变异分析
  • 装置
  • 试剂
  • 其他的

第五章北美分子诊断市场：测试地点的业务分析

  • 北美分子诊断市场：测试位置变化分析
  • 护理点
  • 自我测试或商店测试
  • 中央研究院

第六章北美分子诊断市场：技术业务分析

  • 北美分子诊断市场：技术变迁分析
  • PCR
  • 原位杂合反应(ISH)
  • 恒温核酸增幅技术（INAAT）
  • 晶片和微阵列
  • 质谱
  • 顺序
  • 转录媒介增幅(TMA)
  • 其他的

第七章北美分子诊断市场：应用业务分析

  • 北美分子诊断市场：应用变化分析
  • 肿瘤学
  • 药物基因组学
  • 感染疾病
  • 基因检测
  • 神经系统疾病
  • 循环系统疾病
  • 微生物学
  • 其他的

第八章北美分子诊断市场：国家业务分析

  • 北美洲
    • 美国
    • 加拿大

第九章北美分子诊断市场：竞争形势

  • 参与企业
    • BD
    • Bio-Rad Laboratories, Inc.
    • Abbott
    • Agilent Technologies, Inc.
    • Danaher
    • Hologic Inc. (Gen Probe)
    • Illumina, Inc.
    • Johnson & Johnson Services, Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche, Ltd.
  • 参与企业概况
  • 财务绩效
  • 产品基准评效
  • 2023 年公司市场占有率分析
  • 策略规划

第10章分析师的观点

Product Code: GVR-1-68038-073-6

North America Molecular Diagnostics Market Growth & Trends:

The North America molecular diagnostics market size is expected to reach USD 7.23 billion by 2030, registering a CAGR of 4.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The introduction of technologically advanced products is expected to drive the market in North America. Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens. Molecular diagnostics enable early diagnosis of cancer, genetic disorders, and infectious diseases by using PCR, sequencing, & genetic technologies.

The rise in the prevalence of chronic & infectious diseases and genetic disorders, such as Alzheimer's disease, Turner syndrome, & Parkinson's disease, is expected to boost the market demand during the forecast period. According to the CDC, chronic diseases such as cancer & diabetes and chronic kidney & respiratory diseases are accountable for 7 in 10 deaths in the U.S. each year. Around 6 out of 10 adults are likely to suffer from a chronic disease in the U.S. In addition, the increasing incidence of diseases, such as influenza A & B, is projected to drive market growth. For instance, according to the CDC, in the flu season of 2021-2022, influenza was estimated to affect nine million people.

An increase in external funding to conduct clinical studies in molecular diagnostics is anticipated to fuel the market. Funding plays a significant role in the product development process. For instance, in April 2023, Promega Corporation announced to grant of USD 15,000 in 2023 in academic life sciences research using qPCR. Similarly, in June 2023, Accelerate Diagnostics, Inc. received USD 24 million to accelerate the development of Wave platform and novel rapid testing. Such initiatives are expected to encourage SMEs to be involved in the development of novel molecular diagnostic tests.

Key companies are making continuous efforts to launch new products in North America molecular diagnostics and gain a competitive edge by meeting the changing needs of buyers toward more advanced & efficient products. For instance, in November 2022, Cepheid, a Danaher subsidiary, launched Multiplex Vaginal Panel (MVP), a PCR test to detect various conditions, such as trichomoniasis, bacterial vaginosis, and vulvovaginal candidiasis.

Furthermore, increasing strategic partnerships among manufacturers and companies for developing novel therapeutics is anticipated to drive market growth. For instance, in February 2023, Thermo Fisher Scientific Inc.partnered with MyLab to procure RT-PCR kits for various infectious diseases, such as tuberculosis & HIV. Moreover, in January 2023, QIAGEN and Helix formed an exclusive alliance to enhance next-generation sequencing companion diagnostics in genetic disorders.

North America Molecular Diagnostics Market Report Highlights:

  • Based on the product, the reagents segment accounted for the largest revenue share of North America molecular diagnostics in 2023 owing to improved efficiency and cost-effectiveness
  • The central laboratories segment dominated the North America molecular diagnostics in 2023 owing to high market penetration and large procedure volumes
  • Based on technology, the PCR segment dominated the North America molecular diagnostics in 2023 and is the most preferred technology amongst doctors and patients for clinical diagnostics
  • The infectious disease segment led the application segment in 2023, attributable to North America's high incidence of infectious diseases
  • The U.S. dominated the regional market due to favorable reimbursement policies, the local presence of leading players, and the presence of well-established healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product segment
      • 1.1.1.2. Test Location segment
      • 1.1.1.3. Technology segment
      • 1.1.1.4. Application segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Test Location Snapshot
  • 2.3. Technology and Application Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increase in geriatric population
      • 3.2.1.2. Introduction of technologically advanced products
      • 3.2.1.3. Increase in demand for point-of-care testing
      • 3.2.1.4. Growing prevalence of target diseases
      • 3.2.1.5. Increasing external funding for R&D
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of ambiguous regulatory framework
      • 3.2.2.2. High prices of molecular diagnostics tests
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. North America Molecular Diagnostics Market: Product Business Analysis

  • 4.1. North America Molecular Diagnostics Market: Product Movement Analysis
  • 4.2. Instruments
    • 4.2.1. Instruments Market, 2018 - 2030 (USD Million)
  • 4.3. Reagents
    • 4.3.1. Reagents Market, 2018 - 2030 (USD Million)
  • 4.4. Others
    • 4.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. North America Molecular Diagnostics Market: Test Location Business Analysis

  • 5.1. North America Molecular Diagnostics Market: Test Location Movement Analysis
  • 5.2. Point-of-Care
    • 5.2.1. Point-of-Care Market, 2018 - 2030 (USD Million)
  • 5.3. Self-test or Over the Counter
    • 5.3.1. Self-test or Over the Counter Market, 2018 - 2030 (USD Million)
  • 5.4. Central Laboratories
    • 5.4.1. Central Laboratories Market, 2018 - 2030 (USD Million)

Chapter 6. North America Molecular Diagnostics Market: Technology Business Analysis

  • 6.1. North America Molecular Diagnostics Market: Technology Movement Analysis
  • 6.2. PCR
    • 6.2.1. PCR Market, 2018 - 2030 (USD Million)
      • 6.2.1.1. PCR, by Type
      • 6.2.1.1.1. PCR, by Type Market, 2018 - 2030 (USD Million)
      • 6.2.1.1.1.1. Multiplex PCR
      • 6.2.1.1.1.1.1. Multiplex PCR Market, 2018 - 2030 (USD Million)
      • 6.2.1.1.1.2. Other PCR
      • 6.2.1.1.1.2.1. Other PCR Market, 2018 - 2030 (USD Million)
      • 6.2.1.2. PCR, by Procedure
      • 6.2.1.2.1. PCR, by Procedure Market, 2018 - 2030 (USD Million)
      • 6.2.1.2.1.1. Nucleic Acid Extraction
      • 6.2.1.2.1.1.1. Nucleic Acid Extraction Market, 2018 - 2030 (USD Million)
      • 6.2.1.2.1.2. Others
      • 6.2.1.2.1.2.1. Others Market, 2018 - 2030 (USD Million)
      • 6.2.1.3. PCR, by Product
      • 6.2.1.3.1. PCR, by Product Market, 2018 - 2030 (USD Million)
      • 6.2.1.3.1.1. Instruments
      • 6.2.1.3.1.1.1. Instruments Market, 2018 - 2030 (USD Million)
      • 6.2.1.3.1.2. Reagents
      • 6.2.1.3.1.2.1. Reagents Market, 2018 - 2030 (USD Million)
      • 6.2.1.3.1.3. Others
      • 6.2.1.3.1.3.1. Others Market, 2018 - 2030 (USD Million)
  • 6.3. In Situ Hybridization (ISH)
    • 6.3.1. In Situ Hybridization (ISH) Market, 2018 - 2030 (USD Million)
    • 6.3.2. Instruments
      • 6.3.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.3.3. Reagents
      • 6.3.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.3.4. Others Market, 2018 - 2030 (USD Million)
      • 6.3.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
    • 6.4.1. Isothermal Nucleic Acid Amplification Technology (INAAT) Market, 2018 - 2030 (USD Million)
    • 6.4.2. Instruments
      • 6.4.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.4.3. Reagents
      • 6.4.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.4.4. Others Market, 2018 - 2030 (USD Million)
      • 6.4.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.5. Chips and Microarrays
    • 6.5.1. Chips and Microarrays Market, 2018 - 2030 (USD Million)
    • 6.5.2. Instruments
      • 6.5.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.5.3. Reagents
      • 6.5.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.5.4. Others Market, 2018 - 2030 (USD Million)
      • 6.5.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.6. Mass Spectroscopy
    • 6.6.1. Mass Spectroscopy Market, 2018 - 2030 (USD Million)
    • 6.6.2. Instruments
      • 6.6.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.6.3. Reagents
      • 6.6.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.6.4. Others Market, 2018 - 2030 (USD Million)
      • 6.6.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.7. Sequencing
    • 6.7.1. Sequencing Market, 2018 - 2030 (USD Million)
    • 6.7.2. Instruments
      • 6.7.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.7.3. Reagents
      • 6.7.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.7.4. Others Market, 2018 - 2030 (USD Million)
      • 6.7.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.8. Transcription Mediated Amplification (TMA)
    • 6.8.1. Transcription Mediated Amplification (TMA) Market, 2018 - 2030 (USD Million)
    • 6.8.2. Instruments
      • 6.8.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.8.3. Reagents
      • 6.8.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.8.4. Others Market, 2018 - 2030 (USD Million)
      • 6.8.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market, 2018 - 2030 (USD Million)
    • 6.9.2. Instruments
      • 6.9.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.9.3. Reagents
      • 6.9.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.9.4. Others Market, 2018 - 2030 (USD Million)
      • 6.9.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. North America Molecular Diagnostics Market: Application Business Analysis

  • 7.1. North America Molecular Diagnostics Market: Application Movement Analysis
  • 7.2. Oncology
    • 7.2.1. Oncology Market, 2018 - 2030 (USD Million)
    • 7.2.2. Breast Cancer
      • 7.2.2.1. Breast Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.3. Prostate Cancer
      • 7.2.3.1. Prostate Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.4. Colorectal Cancer Market, 2018 - 2030 (USD Million)
      • 7.2.4.1. Colorectal Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.5. Cervical Cancer
      • 7.2.5.1. Cervical Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.6. Kidney Cancer
      • 7.2.6.1. Kidney Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.7. Liver Cancer Market, 2018 - 2030 (USD Million)
      • 7.2.7.1. Liver Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.8. Blood Cancer
      • 7.2.8.1. Blood Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.9. Lung Cancer
      • 7.2.9.1. Lung Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.10. Other Cancer Market, 2018 - 2030 (USD Million)
      • 7.2.10.1. Other Cancer Market, 2018 - 2030 (USD Million)
  • 7.3. Pharmacogenomics
    • 7.3.1. Pharmacogenomics Market, 2018 - 2030 (USD Million)
  • 7.4. Infectious Diseases
    • 7.4.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
    • 7.4.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
      • 7.4.2.1. Methicillin-resistant Staphylococcus Aureus (MRSA) Market, 2018 - 2030 (USD Million)
    • 7.4.3. Clostridium Difficile
      • 7.4.3.1. Clostridium Difficile Market, 2018 - 2030 (USD Million)
    • 7.4.4. Vancomycin-resistant Enterococci (VRE)
      • 7.4.4.1. Vancomycin-resistant Enterococci (VRE) Market, 2018 - 2030 (USD Million) Instruments
    • 7.4.5. Carbapenem-resistant Bacteria
      • 7.4.5.1. Carbapenem-resistant Bacteria Market, 2018 - 2030 (USD Million)
    • 7.4.6. Flu
      • 7.4.6.1. Flu Market, 2018 - 2030 (USD Million)
    • 7.4.7. Candida Market, 2018 - 2030 (USD Million)
      • 7.4.7.1. Candida Market, 2018 - 2030 (USD Million)
    • 7.4.8. Tuberculosis and Drug-resistant TBA
      • 7.4.8.1. Tuberculosis and Drug-resistant TBA Market, 2018 - 2030 (USD Million)
    • 7.4.9. Meningitis
      • 7.4.9.1. Meningitis Market, 2018 - 2030 (USD Million)
    • 7.4.10. Gastrointestinal Panel Testing
      • 7.4.10.1. Gastrointestinal Panel Testing Market, 2018 - 2030 (USD Million)
    • 7.4.11. Chlamydia
      • 7.4.11.1. Chlamydia Market, 2018 - 2030 (USD Million)
    • 7.4.12. Gonorrhea
      • 7.4.12.1. Gonorrhea Market, 2018 - 2030 (USD Million)
    • 7.4.13. HIV
      • 7.4.13.1. HIV Market, 2018 - 2030 (USD Million)
    • 7.4.14. Hepatitis C
      • 7.4.14.1. Hepatitis C Market, 2018 - 2030 (USD Million)
    • 7.4.15. Hepatitis B
      • 7.4.15.1. Hepatitis B Market, 2018 - 2030 (USD Million)
    • 7.4.16. Others Infectious Diseases
      • 7.4.16.1. Other Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 7.5. Genetic Testing
    • 7.5.1. Genetic Testing Market, 2018 - 2030 (USD Million)
    • 7.5.2. Newborn Screening
      • 7.5.2.1. Newborn Screening Market, 2018 - 2030 (USD Million)
    • 7.5.3. Predictive and Presymptomatic Testing
      • 7.5.3.1. Predictive and Presymptomatic Market, 2018 - 2030 (USD Million)
    • 7.5.4. Other Genetic Testing Market, 2018 - 2030 (USD Million) Instruments
      • 7.5.4.1. Other Genetic Testing Market, 2018 - 2030 (USD Million)
  • 7.6. Neurological Disease
    • 7.6.1. Neurological Disease Market, 2018 - 2030 (USD Million)
  • 7.7. Cardiovascular Disease
    • 7.7.1. Cardiovascular Disease Market, 2018 - 2030 (USD Million)
  • 7.8. Microbiology
    • 7.8.1. Microbiology Market, 2018 - 2030 (USD Million)
  • 7.9. Others
    • 7.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. North America Molecular Diagnostics Market: Country Business Analysis

  • 8.1. North America
    • 8.1.1. North America Molecular Diagnostics Market, 2018 - 2030 (USD Million)
    • 8.1.2. U.S.
      • 8.1.2.1. Key Country Dynamics
      • 8.1.2.2. Target Disease Prevalence
      • 8.1.2.3. Competitive Scenario
      • 8.1.2.4. Regulatory Framework
      • 8.1.2.5. U.S. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
    • 8.1.3. Canada
      • 8.1.3.1. Key Country Dynamics
      • 8.1.3.2. Target Disease Prevalence
      • 8.1.3.3. Competitive Scenario
      • 8.1.3.4. Regulatory Framework
      • 8.1.3.5. Canada Molecular Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 9. North America Molecular Diagnostics Market: Competitive Landscape

  • 8.1. Participant Categorization
    • 9.1.1. BD
      • 9.1.1.1. Overview
      • 9.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.1.3. Product Benchmarking
      • 9.1.1.4. Strategic Initiatives
    • 9.1.2. Bio-Rad Laboratories, Inc.
      • 9.1.2.1. Overview
      • 9.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.2.3. Product Benchmarking
      • 9.1.2.4. Strategic Initiatives
    • 9.1.3. Abbott
      • 9.1.3.1. Overview
      • 9.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.3.3. Product Benchmarking
      • 9.1.3.4. Strategic Initiatives
    • 9.1.4. Agilent Technologies, Inc.
      • 9.1.4.1. Overview
      • 9.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.4.3. Product Benchmarking
      • 9.1.4.4. Strategic Initiatives
    • 9.1.5. Danaher
      • 9.1.5.1. Overview
      • 9.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.5.3. Product Benchmarking
      • 9.1.5.4. Strategic Initiatives
    • 9.1.6. Hologic Inc. (Gen Probe)
      • 9.1.6.1. Overview
      • 9.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.6.3. Product Benchmarking
      • 9.1.6.4. Strategic Initiatives
    • 9.1.7. Illumina, Inc.
      • 9.1.7.1. Overview
      • 9.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.7.3. Product Benchmarking
      • 9.1.7.4. Strategic Initiatives
    • 9.1.8. Johnson & Johnson Services, Inc.
      • 9.1.8.1. Overview
      • 9.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.8.3. Product Benchmarking
      • 9.1.8.4. Strategic Initiatives
    • 9.1.9. Thermo Fisher Scientific Inc.
      • 9.1.9.1. Overview
      • 9.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.9.3. Product Benchmarking
      • 9.1.9.4. Strategic Initiatives
    • 9.1.10. F. Hoffmann-La Roche, Ltd.
      • 9.1.10.1. Overview
      • 9.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.10.3. Product Benchmarking
      • 9.1.10.4. Strategic Initiatives
  • 9.2. Participant's Overview
  • 9.3. Financial Performance
  • 9.4. Product Benchmarking
  • 9.5. Company Market Share Analysis, 2023
  • 9.6. Strategy Mapping
    • 9.6.1. Expansion
    • 9.6.2. Acquisition
    • 9.6.3. Product/Service Launch
    • 9.6.4. Others

Chapter 10. Analyst View

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Molecular Diagnostics Market, By Country, 2018 - 2030 (USD Million)
  • Table 4 North America Molecular Diagnostics Market, By Product, 2018 - 2030 (USD Million)
  • Table 5 North America Molecular Diagnostics Market, By Test Location, 2018 - 2030 (USD Million)
  • Table 6 North America Molecular Diagnostics Market, By Technology, 2018 - 2030 (USD Million)
  • Table 7 North America Molecular Diagnostics market, by Application, 2018 - 2030 (USD Million)
  • Table 8 U.S. Molecular Diagnostics market, by Product, 2018 - 2030 (USD Million)
  • Table 9 U.S. Molecular Diagnostics market, by Test Location, 2018 - 2030 (USD Million)
  • Table 10 U.S. Molecular Diagnostics Market, By Technology, 2018 - 2030 (USD Million)
  • Table 11 U.S. Molecular Diagnostics market, by Application, 2018 - 2030 (USD Million)
  • Table 12 Canada Molecular Diagnostics market, by Product, 2018 - 2030 (USD Million)
  • Table 13 Canada Molecular Diagnostics market, by Test Location, 2018 - 2030 (USD Million)
  • Table 14 Canada Molecular Diagnostics Market, By Technology, 2018 - 2030 (USD Million)
  • Table 15 Canada Molecular Diagnostics market, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 North America molecular diagnostics market segmentation
  • Fig. 8 Market snapshot, 2023
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 Market challenge relevance analysis (current & future impact)
  • Fig. 13 SWOT analysis
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 North America molecular diagnostics market: Product movement analysis
  • Fig. 16 Instruments market, 2018 - 2030 (USD Million)
  • Fig. 17 Reagents market, 2018 - 2030 (USD Million)
  • Fig. 18 Others market, 2018 - 2030 (USD Million)
  • Fig. 19 North America molecular diagnostics market: Test location movement analysis
  • Fig. 20 Point of care market, 2018 - 2030 (USD Million)
  • Fig. 21 Self-test or OTC market, 2018 - 2030 (USD Million)
  • Fig. 22 Central laboratories market, 2018 - 2030 (USD Million)
  • Fig. 23 North America molecular diagnostics market: Technology movement analysis
  • Fig. 24 PCR market, 2018 - 2030 (USD Million)
  • Fig. 25 Nucleic Acid Extraction PCR market, 2018 - 2030 (USD Million)
  • Fig. 26 Others PCR market, 2018 - 2030 (USD Million)
  • Fig. 27 Multiplex PCR market, 2018 - 2030 (USD Million)
  • Fig. 28 Other PCR market, 2018 - 2030 (USD Million)
  • Fig. 29 In Situ Hybridization market, 2018 - 2030 (USD Million)
  • Fig. 30 Isothermal Nucleic Acid Amplification Technology (INAAT) market, 2018 - 2030 (USD Million)
  • Fig. 31 Chips and microarrays market, 2018 - 2030 (USD Million)
  • Fig. 32 Mass spectrometry market, 2018 - 2030 (USD Million)
  • Fig. 33 Sequencing market, 2018 - 2030 (USD Million)
  • Fig. 34 Transcription mediated amplification market, 2018 - 2030 (USD Million)
  • Fig. 35 Others market, 2018 - 2030 (USD Million)
  • Fig. 36 North America molecular diagnostics market: Application movement analysis
  • Fig. 37 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 38 Breast cancer market, 2018 - 2030 (USD Million)
  • Fig. 39 Prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 40 Colorectal cancer market, 2018 - 2030 (USD Million)
  • Fig. 41 Cervical cancer market, 2018 - 2030 (USD Million)
  • Fig. 42 Kidney cancer market, 2018 - 2030 (USD Million)
  • Fig. 43 Liver cancer market, 2018 - 2030 (USD Million)
  • Fig. 44 Blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 45 Lung cancer market, 2018 - 2030 (USD Million)
  • Fig. 46 Other cancer market, 2018 - 2030 (USD Million)
  • Fig. 47 Pharmacogenomics market, 2018 - 2030 (USD Million)
  • Fig. 48 Infectious disease market, 2018 - 2030 (USD Million)
  • Fig. 49 MRSA market, 2018 - 2030 (USD Million)
  • Fig. 50 Clostridium difficile market, 2018 - 2030 (USD Million)
  • Fig. 51 Vancomycin-resistant enterococci market, 2018 - 2030 (USD Million)
  • Fig. 52 Carbapenem-resistant bacteria testing market, 2018 - 2030 (USD Million)
  • Fig. 53 Flu market, 2018 - 2030 (USD Million)
  • Fig. 54 Respiratory syncytial virus (RSV) market, 2018 - 2030 (USD Million)
  • Fig. 55 Candida market, 2018 - 2030 (USD Million)
  • Fig. 56 Tuberculosis and drug-resistant TB market, 2018 - 2030 (USD Million)
  • Fig. 57 Meningitis market, 2018 - 2030 (USD Million)
  • Fig. 58 Gastro-intestinal panel testing market, 2018 - 2030 (USD Million)
  • Fig. 59 Chlamydia market, 2018 - 2030 (USD Million)
  • Fig. 60 Gonorrhea market, 2018 - 2030 (USD Million)
  • Fig. 61 HIV market, 2018 - 2030 (USD Million)
  • Fig. 62 Hepatitis C market, 2018 - 2030 (USD Million)
  • Fig. 63 Hepatitis B market, 2018 - 2030 (USD Million)
  • Fig. 64 Other infectious diseases market, 2018 - 2030 (USD Million)
  • Fig. 65 Genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 66 Newborn screening market, 2018 - 2030 (USD Million)
  • Fig. 67 Predictive and presymptomatic testing market, 2018 - 2030 (USD Million)
  • Fig. 68 Others market, 2018 - 2030 (USD Million)
  • Fig. 69 Neurological disease market, 2018 - 2030 (USD Million)
  • Fig. 70 Cardiovascular disease market, 2018 - 2030 (USD Million)
  • Fig. 71 Microbiology market, 2018 - 2030 (USD Million)
  • Fig. 72 Others market, 2018 - 2030 (USD Million)
  • Fig. 73 Regional marketplace: key takeaways
  • Fig. 74 Regional outlook, 2023 & 2030
  • Fig. 75 North America molecular diagnostics market: Country movement analysis.
  • Fig. 76 North America molecular diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 77 U.S. key country dynamics
  • Fig. 78 U.S. molecular diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 79 Canada key country dynamics
  • Fig. 80 Canada molecular diagnostics market, 2018 - 2030 (USD Million)